KRAS and non-small cell lung carcinoma: We employed our robust isogenic system [5], and applied a targeted metabolomics strategy to profile the metabolic cellular responses after the inhibition of PI3K signaling in NSCLC clones harboring KRAS-G12C or -WT isoforms.